All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2024; the latest 2026-07-31.
From the record
Cellyan Biotechnology Co., Ltd's filings since 2024 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2026-07-31) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+27.2% a year over 3 filed years; profitable in 2 of 3.
From the record
Cellyan Biotechnology Co., Ltd's 3 filed years say what it did: revenue went from $13 million in fiscal 2023 to $20 million in fiscal 2025, up 27.2% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 2 of 3 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 22.1% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.
From the record
Over the 2 fiscal years to 2025-03-31, Cellyan Biotechnology Co., Ltd's diluted share count grew about 22.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE -1%: lost 1¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-03-31, Cellyan Biotechnology Co., Ltd lost about 1 cents for every dollar of shareholders' money, and gross profitability: its products earned about 26 cents per dollar of everything the company owns. Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count grew 38.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 48% of 10 in its family; net margin -0.1%.
From the record
Cellyan Biotechnology Co., Ltd's standing among 10 graded names in its industry family: revenue of $20 million in fiscal 2025 ranks in the bottom 15% by size; a net margin of -0.1% ranks in the bottom 45%; revenue growth of 27.2% a year over the last 2 filed years ranks in the top 15% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Cellyan Biotechnology Co., Ltd's leadership is put at 5.3 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-06-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 5 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 9 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 45% of 10 in its family for room to expand.
From the record
Cellyan Biotechnology Co., Ltd's room to grow, from the newest filed statements (fiscal 2025): cash of $749 thousand against debt of $2 million leaves -12% of its assets as net cash, bottom 35% of its family; cash from operations less capital spending is 2.5% of revenue (top 25%); a gross margin of 11.9% (top 45%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 40% of 8 in its family for growth drivers.
From the record
Cellyan Biotechnology Co., Ltd's growth drivers, from the filed years to fiscal 2025: revenue grew 27.2% a year over the last three filed years against 27.2% over all 3, speeding up (top 31% of its family); the newest year grew 21.7% (top 6%); capital spending grew -21.9% a year (bottom 19%) (its annual reports). Cellyan Biotechnology Co., Ltd tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.5/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Cellyan Biotechnology Co., Ltd's expectations vs reality is put at 5.5 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 7 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made